Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

Core Viewpoint - Nuwellis, Inc. has successfully closed a public offering, raising approximately $5.0 million through the sale of common stock and warrants, aimed at transforming care for fluid overload patients [1][2]. Summary by Sections Public Offering Details - The offering included 2,580,667 shares of common stock and pre-funded warrants to purchase 14,085,998 shares, along with Series A and Series B Warrants [1]. - The public offering price was set at $0.30 per share and accompanying warrants, while the pre-funded warrants were priced at $0.2999 [2]. Warrant Specifications - Pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable until fully exercised [3]. - Series A and Series B Warrants have an exercise price of $0.30 and will be exercisable for five years post stockholder approval [3]. - Series A Warrants include a one-time reset of the exercise price in case of a reverse stock split, while Series B Warrants offer a zero cash exercise option [3]. Underwriter Information - Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering [4]. Regulatory Compliance - The securities are offered under a registration statement on Form S-1, which was declared effective by the SEC on June 9, 2025 [5].